272. Fibrodysplasia ossificans progressiva
23 clinical trials,   21 drugs   (DrugBank: 4 drugs),   10 drug target genes,   87 drug target pathways

Searched query = "Fibrodysplasia ossificans progressiva", "FOP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04307953
(ClinicalTrials.gov)
August 5, 202011/3/2020Saracatinib Trial TO Prevent FOPSaracatinib Trial TO Prevent FOPFibrodysplasia Ossificans ProgressivaDrug: AZD0530 Difumarate;Drug: Matching placeboVU University Medical CenterRoyal National Orthopaedic Hospital NHS Trust;Klinikum Garmisch-Patenkirchen;University of Oxford;Brigham and Women's Hospital;AstraZeneca;Innovative Medicines InitiativeRecruiting18 Years65 YearsAll20Phase 2Germany;Netherlands;United Kingdom
2EUCTR2019-003324-20-NL
(EUCTR)
08/01/202016/10/2019A clinical trial to judge the safety, tolerability and effects on abnormal bone formation of reseach medication AZD 0530 (sarcatinib) in patients with FOPSaracatinib trial TO Prevent FOP - STOPFOP Fibrodyplasia Ossificans Progressiva (FOP)
MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: Saracatinib
Product Code: AZD0530
INN or Proposed INN: Saracatinib
Other descriptive name: SARACATINIB DIFUMARATE
VU University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
16Phase 2Netherlands